Literature DB >> 29373089

Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer.

Pritesh Patel1, Melvy S Mathew1, Igor Trilisky1, Aytekin Oto1.   

Abstract

The use of multiparametric magnetic resonance (MR) imaging in prostate cancer therapy is increasing, as newer treatment methods and management approaches emerge. The mainstays of therapy-radiation and surgery-are being supplemented (and even replaced) by novel focal therapy methods. Laser and ultrasonographic ablation, photodynamic therapy, electroporation, and cryoablation are the most common focal therapies, each with its own imaging findings. Typical ablation zones have a central focus of enhancement with peripheral rim enhancement; thus, dynamic contrast material-enhanced (DCE) MR imaging is the most important sequence for evaluation of treatment in the immediate posttherapeutic setting. Detection of recurrence can initiate salvage therapy, but recurrence can be difficult to detect on T2-weighted images, again necessitating DCE MR imaging and also diffusion-weighted imaging. Furthermore, the location of recurrence can vary depending on the therapy. With radiation therapy, the most common site of recurrence is the prior tumor site, whereas after prostatectomy, the recurrence usually occurs around the vesicoureteral anastomosis. Regarding management, there is an increased emphasis on watchful waiting and active surveillance, for which MR imaging has a critical role in both selection and follow-up of patients who undergo active surveillance. As MR imaging is being increasingly used for imaging suspected recurrence, it is important for radiologists to be familiar with the normal posttreatment findings and patterns and MR imaging findings of recurrence. ©RSNA, 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29373089     DOI: 10.1148/rg.2018170147

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  12 in total

1.  Role of MRI for the detection of prostate cancer.

Authors:  Richard C Wu; Amir H Lebastchi; Boris A Hadaschik; Mark Emberton; Caroline Moore; Pilar Laguna; Jurgen J Fütterer; Arvin K George
Journal:  World J Urol       Date:  2021-01-04       Impact factor: 4.226

2.  Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.

Authors:  Baowei Fei; Olayinka A Abiodun-Ojo; Akinyemi A Akintayo; Oladunni Akin-Akintayo; Funmilayo Tade; Peter T Nieh; Viraj A Master; Mehrdad Alemozaffar; Adeboye O Osunkoya; Mark M Goodman; David M Schuster
Journal:  J Urol       Date:  2019-07-08       Impact factor: 7.450

3.  18F-Fluciclovine Parameters on Targeted Prostate Biopsy Associated with True Positivity in Recurrent Prostate Cancer.

Authors:  Olayinka A Abiodun-Ojo; Akinyemi A Akintayo; Oladunni O Akin-Akintayo; Funmilayo I Tade; Peter T Nieh; Viraj A Master; Mehrdad Alemozaffar; Adeboye O Osunkoya; Mark M Goodman; Baowei Fei; David M Schuster
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

4.  Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient's perspective.

Authors:  Marieke van Son; Evelyn Monninkhof; Max Peters; Jan Lagendijk; Jochem van der Voort van Zyp
Journal:  Clin Transl Radiat Oncol       Date:  2020-10-17

5.  Patient Demographics and Referral Patterns for [F-18]Fluciclovine-PET Imaging at a Tertiary Academic Medical Center.

Authors:  Samuel J Galgano; Carli E Calderone; Andrew M McDonald; Jeffrey W Nix; Mollie deShazo; Eddy S Yang; Jonathan E McConathy; Soroush Rais-Bahrami
Journal:  J Am Coll Radiol       Date:  2018-11-14       Impact factor: 5.532

Review 6.  Dynamic contrast-enhanced (DCE) imaging: state of the art and applications in whole-body imaging.

Authors:  Domenico Albano; Federico Bruno; Andrea Agostini; Salvatore Alessio Angileri; Massimo Benenati; Giulia Bicchierai; Michaela Cellina; Vito Chianca; Diletta Cozzi; Ginevra Danti; Federica De Muzio; Letizia Di Meglio; Francesco Gentili; Giuliana Giacobbe; Giulia Grazzini; Irene Grazzini; Pasquale Guerriero; Carmelo Messina; Giuseppe Micci; Pierpaolo Palumbo; Maria Paola Rocco; Roberto Grassi; Vittorio Miele; Antonio Barile
Journal:  Jpn J Radiol       Date:  2021-12-24       Impact factor: 2.374

Review 7.  Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives.

Authors:  Marieke van Son; Max Peters; Marinus Moerland; Linda Kerkmeijer; Jan Lagendijk; Jochem van der Voort van Zyp
Journal:  Cancers (Basel)       Date:  2018-12-03       Impact factor: 6.639

8.  Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer.

Authors:  Mark Paxton; Eitan Barbalat; Nathan Perlis; Ravi J Menezes; Mark Gertner; David Dragas; Masoom A Haider; Antonio Finelli; John Trachtenberg; Sangeet Ghai
Journal:  Br J Radiol       Date:  2021-07-29       Impact factor: 3.039

9.  Optimizing patient selection for focal therapy-mapping and ablating the index lesion.

Authors:  James S Wysock; Herbert Lepor
Journal:  Transl Androl Urol       Date:  2018-09

Review 10.  Prostate minimally invasive procedures: complications and normal vs. abnormal findings on multiparametric magnetic resonance imaging (mpMRI).

Authors:  Thanh-Lan Bui; Justin Glavis-Bloom; Chantal Chahine; Raj Mehta; Taylor Wolfe; Param Bhatter; Mark Rupasinghe; Joseph Carbone; Masoom A Haider; Francesco Giganti; Simone Giona; Aytekin Oto; Grace Lee; Roozbeh Houshyar
Journal:  Abdom Radiol (NY)       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.